| Bioactivity | Ianalumab (VAY-736) is a humanized, decarboxylated antibody against BAFF-R. Ianalumab can block the interaction between BAFF and BAFF-R and antagonize the apoptosis protection mediated by BAFF. Ianalumab exerts antibody-dependent cytotoxic (ADCC), depending on effector cell activation mediated by immune receptor tyrosine activation motif (ITAM)[1]. |
| Target | BAFF-R |
| Invitro | Ianalumab (0.1 μg/mL; 72 h) 对慢性淋巴细胞白血病 (CLL) 自然杀伤细胞的强抗体依赖性细胞毒性 (ADCC)，促进细胞因子的产生[1]。 |
| In Vivo | Ianalumab (总剂量: 100 mg/kg; 每周一次, 持续 2 周) 增加 CLL 小鼠模型的小鼠存活率[1]。Ianalumab (10 mg/kg; 每周一次, 持续 6 周) 经 Ibrutinib (HY-10997) 调节 NK 细胞的 ITAM 后，表现出功能增强[1]。 Animal Model: |
| Name | Ianalumab |
| CAS | 1929549-92-7 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. McWilliams EM, et al. Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib. Blood Adv. 2019 Feb 12;3(3):447-460. |